2024
Acupuncture for Chronic Radiation-Induced Xerostomia in Head and Neck Cancer
Cohen L, Danhauer S, Garcia M, Dressler E, Rosenthal D, Chambers M, Cusimano A, Brown W, Ochoa J, Yang P, Chiang J, Gordon O, Crutcher R, Kim J, Russin M, Lukenbill J, Porosnicu M, Yost K, Weaver K, Lesser G. Acupuncture for Chronic Radiation-Induced Xerostomia in Head and Neck Cancer. JAMA Network Open 2024, 7: e2410421. PMID: 38739392, PMCID: PMC11091764, DOI: 10.1001/jamanetworkopen.2024.10421.Peer-Reviewed Original ResearchConceptsSham acupunctureTrue acupunctureTreating radiation-induced xerostomiaHead and neck cancerFunctional Assessment of Cancer Therapy-General scoresRadiation-induced xerostomiaBenefits of acupunctureQuestionnaire scoresCommunity-based cancer centerNeck cancerPatient-reported outcomesRisk of biasQuality of lifeTreated 2 timesAcupuncture studiesGroup differencesStatistically significant group differencesBetween-group differencesAcupunctureXerostomia questionnaire scoreMain OutcomesSignificant group differencesFunctional assessmentStudy armsCancer CenterSurrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis
Gharzai L, Morris E, Suresh K, Nguyen-Tân P, Rosenthal D, Gillison M, Harari P, Garden A, Koyfman S, Caudell J, Jones C, Mitchell D, Krempl G, Ridge J, Gensheimer M, Bonner J, Filion E, Dunlap N, Stokes W, Le Q, Torres-Saavedra P, Mierzwa M, Schipper M. Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis. The Lancet Oncology 2024, 25: 366-375. PMID: 38423050, PMCID: PMC10962533, DOI: 10.1016/s1470-2045(24)00016-0.Peer-Reviewed Original ResearchConceptsLocoregional progression-free survivalProgression-free survivalIntermediate clinical endpointsMetastasis-free survivalOverall survivalClinical endpointsOropharyngeal cancerComposite endpointIncidence of human papillomavirus (HPV)-related cancersP16-positive squamous cell carcinomaHuman papillomavirus (HPV)-related cancersP16-positive oropharyngeal cancerCancer treated with chemotherapyIndividual patient data meta-analysisMedian follow-upPatient data meta-analysisSquamous-cell carcinomaSquamous cell carcinomaPatient levelClinical trial endpointsTreatment effectsData meta-analysisLocoregional progressionNational Cancer InstituteDistant metastasis
2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Ferrarotto R, Amit M, Nagarajan P, Rubin M, Yuan Y, Bell D, El-Naggar A, Johnson J, Morrison W, Rosenthal D, Glisson B, Johnson F, Lu C, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis C, Weber R, Wargo J, Basu S, Duan F, Yadav S, Sharma P, Allison J, Myers J, Gross N. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research 2021, 27: 4557-4565. PMID: 34187851, PMCID: PMC8711237, DOI: 10.1158/1078-0432.ccr-21-0585.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaInflamed tumor microenvironmentSquamous cell carcinomaHead and neckCSCC-HNNeoadjuvant immunotherapyCell carcinomaTumor microenvironmentPathological responsePD-1 inhibitionCurative-intent surgeryPathological response rateBiomarkers of responseT cell clustersOS ratesNeoadjuvant treatmentPartial responseRecurrent diseaseExploratory endpointsPrimary endpointSecondary endpointsImmune biomarkersFollow-upCyTOF analysisPatients
2017
Conditional Survival Analysis of Patients With Locally Advanced Laryngeal Cancer: Construction of a Dynamic Risk Model and Clinical Nomogram
Sheu T, Vock D, Mohamed A, Gross N, Mulcahy C, Zafereo M, Gunn G, Garden A, Sevak P, Phan J, Lewin J, Frank S, Beadle B, Morrison W, Lai S, Hutcheson K, Marai G, Canahuate G, Kies M, El-Naggar A, Weber R, Rosenthal D, Fuller C. Conditional Survival Analysis of Patients With Locally Advanced Laryngeal Cancer: Construction of a Dynamic Risk Model and Clinical Nomogram. Scientific Reports 2017, 7: 43928. PMID: 28276466, PMCID: PMC5343446, DOI: 10.1038/srep43928.Peer-Reviewed Original ResearchConceptsConditional overall survivalRecurrence free survivalLocally advanced laryngeal cancerOverall survivalAdvanced laryngeal cancerYears of survivalConditional survivalLaryngeal cancerYear actuarial overall survivalActuarial overall survivalTreatment-related toxicityAssociated with recurrenceSurvival analysis of patientsAnalysis of patientsFollow-up timeRecords of patientsConditional survival analysisNodal diseaseFree survivalPrognostic factorsNodal groupsPredictive nomogramClinical nomogramHigher mortality riskPatient cohort
2016
Dynamic contrast-enhanced MRI detects acute radiotherapy-induced alterations in mandibular microvasculature: prospective assessment of imaging biomarkers of normal tissue injury
Sandulache V, Hobbs B, Mohamed A, Frank S, Song J, Ding Y, Ger R, Court L, Kalpathy-Cramer J, Hazle J, Wang J, Awan M, Rosenthal D, Garden A, Gunn G, Colen R, Elshafeey N, Elbanan M, Hutcheson K, Lewin J, Chambers M, Hofstede T, Weber R, Lai S, Fuller C. Dynamic contrast-enhanced MRI detects acute radiotherapy-induced alterations in mandibular microvasculature: prospective assessment of imaging biomarkers of normal tissue injury. Scientific Reports 2016, 6: 29864. PMID: 27499209, PMCID: PMC4976364, DOI: 10.1038/srep29864.Peer-Reviewed Original ResearchConceptsDCE-MRIBone vascularizationHead and neck tumorsHead and neck cancerProspective imaging trialExternal beam radiotherapyDynamic contrast-enhanced MRINormal tissue injuryNormal tissue toxicityDCE-MRI scansContrast-enhanced MRIDetect dose-dependent changesDose-dependent alterationsDose-dependent changesMulti-parametric MRIBeam radiotherapyNeck tumorsTissue toxicityNeck cancerInstitutional experienceVascular injuryTissue injuryImaging trialsKtransImaging modalities